Thiotepa
Clinical data | |||
---|---|---|---|
Trade names | Tepadina | ||
AHFS/Drugs.com | Monograph | ||
MedlinePlus | a682821 | ||
License data | |||
Pregnancy category |
| ||
Routes of administration | Intravenous, intracavitary, intravesical | ||
ATC code | |||
Legal status | |||
Legal status | |||
Pharmacokinetic data | |||
Metabolism | Liver (CYP2B6, CYP3A) | ||
Elimination half-life | 1.5–4.1 hours | ||
Excretion | Kidney 6 hours for thiotepa 8 hours for TEPA | ||
Identifiers | |||
| |||
JSmol) | |||
| |||
| |||
(what is this?) (verify) |
Thiotepa (INN[6]), sold under the brand name Tepadina, is a medication used to treat cancer.[4][5][7]
Thiotepa is an
Medical uses
Thiotepa is indicated for use in combination with other
Thiotepa is used in the palliation of many neoplastic diseases. The best results are found in the treatment of adenocarcinoma of the breast, adenocarcinoma of the ovary, papillary thyroid cancer and bladder cancer. Thiotepa is used to control intracavitary effusions caused by serosal neoplastic deposits.[7]
Intravesical use
Thiotepa is used as intravesical chemotherapy in bladder cancer.[9]
It may be used prophylactically to prevent seeding of tumor cells at cystoscopic biopsy; as an adjunctive agent at the time of biopsy; or as a therapeutic agent to prevent recurrence after cystoscopic resection of bladder tumor (
Side effects
The main side effect of thiotepa is bone marrow suppression resulting in leukopenia, thrombocytopenia and anemia.[10] Liver and lung toxicity may also occur.[medical citation needed]
History
Thiotepa was developed by the American Cyanamid company in the early 1950s and reported to media outlets in 1953.[11] In 1959, thiotepa was registered with the Food and Drug Administration (FDA) as a drug therapy for several solid cancers.[12]
In January 2007, the European Medicines Agency (EMA) designated thiotepa as an orphan drug. In April 2007, the United States FDA designated thiotepa as a conditioning treatment for use prior to hematopoietic stem cell transplantation.[13]
References
- FDA. Retrieved 22 October 2023.
- ^ "Tepadina (Link Medical Products Pty Ltd T/A Link Pharmaceuticals)". Therapeutic Goods Administration (TGA). 28 September 2022. Archived from the original on 18 March 2023. Retrieved 29 April 2023.
- ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ a b c "Tepadina- thiotepa injection, powder, for solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.
- ^ a b c d e "Tepadina EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 March 2021. Retrieved 30 April 2021.
- ^ "International Non-Proprietary Names for Pharmaceutical Preparations. Recommended International Non-Proprietary Names (Rec. I.N.N.): List 4" (PDF). World Health Organization. March 1962. p. 111. Archived (PDF) from the original on 18 May 2016. Retrieved 27 November 2016.
- ^ a b c d e f "Urgent, Thiotepa update" (PDF). U.S. Food and Drug Administration (FDA). 5 April 2011. Archived (PDF) from the original on 9 November 2011. Retrieved 25 November 2011.
- PMID 10913381.
- ISBN 978-1-55009-173-1. Archivedfrom the original on 11 January 2023. Retrieved 16 September 2017.
- PMID 6812036.
- .
- ISBN 978-94-024-0844-7.
- ^ "EMA Grants Adienne Marketing Rights for Tepadina". Drug Discovery & Development. 19 March 2010. Retrieved 25 November 2011.